Drug intelligence / Profile preview

IVW-1802

Development stage: Preclinical
Lead developer: IVIEW Therapeutics
Modality: Small Molecules
Administration: Ophthalmic

Overview

IVW-1802 is a preclinical-stage small molecule muscarinic acetylcholine receptor (mAChR) antagonist being developed by IVIEW Therapeutics for the treatment of myopia (nearsightedness). Muscarinic antagonists are a recognized class of therapeutics for myopia, as they are thought to slow the progression of the condition by inhibiting the axial elongation of the eye. IVW-1802 is part of IVIEW Therapeutics' pipeline of innovative ophthalmic treatments, which focuses on addressing various eye diseases through small molecule and gene therapy approaches.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on IVW-1802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVW-1802.

Explore the full profile